Koers A1M Pharma AB Nasdaq Stockholm
Aandelen
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- SEK | - |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 292 mln. 27,36 mln. 25,22 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -99 mln. -9,28 mln. -8,56 mln. | Nettowinst (verlies) 2025 * | -99 mln. -9,28 mln. -8,56 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | 70 mln. 6,56 mln. 6,05 mln. | Nettoliquiditeiten 2025 * | 46 mln. 4,31 mln. 3,98 mln. | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-2,94
x | K/w-verhouding 2025 * |
-2,94
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 60,37% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 48 | 01-12-18 | |
Karin Botha
DFI | Director of Finance/CFO | 51 | 14-09-20 |
Michael Reusch
CTO | Chief Tech/Sci/R&D Officer | 64 | 01-01-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Johan Bygge
CHM | Chairman | 68 | 01-05-21 |
Göran Forsberg
BRD | Director/Board Member | 61 | 29-05-19 |
Fredrik Lehmann
BRD | Director/Board Member | 48 | 01-12-22 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+67,53% | 63,85 mld. | |
-0,77% | 41,83 mld. | |
+45,66% | 40,65 mld. | |
-10,72% | 27,12 mld. | |
+13,30% | 26,52 mld. | |
-22,79% | 18,69 mld. | |
+4,70% | 12,73 mld. | |
+24,10% | 12,11 mld. | |
+27,41% | 12,07 mld. |
- Beurs
- Aandelen
- Koers GUARD
- Koers